|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF280D |
Gene summary for ZNF280D |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF280D | Gene ID | 54816 |
| Gene name | zinc finger protein 280D | |
| Gene Alias | SUHW4 | |
| Cytomap | 15q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6N043 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54816 | ZNF280D | LZE2T | Human | Esophagus | ESCC | 5.80e-05 | 4.14e-01 | 0.082 |
| 54816 | ZNF280D | LZE3D | Human | Esophagus | HGIN | 1.76e-02 | 4.34e-01 | 0.0668 |
| 54816 | ZNF280D | LZE4T | Human | Esophagus | ESCC | 1.94e-18 | 5.33e-01 | 0.0811 |
| 54816 | ZNF280D | LZE5T | Human | Esophagus | ESCC | 6.03e-08 | 4.63e-01 | 0.0514 |
| 54816 | ZNF280D | LZE7T | Human | Esophagus | ESCC | 4.18e-14 | 5.12e-01 | 0.0667 |
| 54816 | ZNF280D | LZE8T | Human | Esophagus | ESCC | 3.74e-09 | 2.34e-01 | 0.067 |
| 54816 | ZNF280D | LZE20T | Human | Esophagus | ESCC | 3.65e-03 | 1.01e-01 | 0.0662 |
| 54816 | ZNF280D | LZE22T | Human | Esophagus | ESCC | 4.29e-06 | 2.28e-01 | 0.068 |
| 54816 | ZNF280D | LZE24T | Human | Esophagus | ESCC | 2.64e-12 | 1.67e-01 | 0.0596 |
| 54816 | ZNF280D | LZE21T | Human | Esophagus | ESCC | 1.58e-08 | 4.57e-01 | 0.0655 |
| 54816 | ZNF280D | LZE6T | Human | Esophagus | ESCC | 3.11e-06 | 3.17e-01 | 0.0845 |
| 54816 | ZNF280D | P1T-E | Human | Esophagus | ESCC | 9.03e-17 | 5.76e-01 | 0.0875 |
| 54816 | ZNF280D | P2T-E | Human | Esophagus | ESCC | 2.15e-32 | 5.95e-01 | 0.1177 |
| 54816 | ZNF280D | P4T-E | Human | Esophagus | ESCC | 2.79e-36 | 6.21e-01 | 0.1323 |
| 54816 | ZNF280D | P5T-E | Human | Esophagus | ESCC | 2.50e-17 | 3.81e-01 | 0.1327 |
| 54816 | ZNF280D | P8T-E | Human | Esophagus | ESCC | 2.22e-35 | 5.92e-01 | 0.0889 |
| 54816 | ZNF280D | P9T-E | Human | Esophagus | ESCC | 2.95e-30 | 5.06e-01 | 0.1131 |
| 54816 | ZNF280D | P10T-E | Human | Esophagus | ESCC | 1.12e-44 | 7.41e-01 | 0.116 |
| 54816 | ZNF280D | P11T-E | Human | Esophagus | ESCC | 9.65e-23 | 4.75e-01 | 0.1426 |
| 54816 | ZNF280D | P12T-E | Human | Esophagus | ESCC | 3.96e-42 | 8.26e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF280D | SNV | Missense_Mutation | c.2923G>A | p.Glu975Lys | p.E975K | Q6N043 | protein_coding | tolerated_low_confidence(0.08) | benign(0.015) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF280D | SNV | Missense_Mutation | novel | c.647N>A | p.Ser216Tyr | p.S216Y | Q6N043 | protein_coding | tolerated(0.05) | possibly_damaging(0.646) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ZNF280D | SNV | Missense_Mutation | rs866653627 | c.2773G>A | p.Glu925Lys | p.E925K | Q6N043 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF280D | SNV | Missense_Mutation | novel | c.1730N>T | p.Thr577Ile | p.T577I | Q6N043 | protein_coding | tolerated(0.05) | benign(0.046) | TCGA-B6-A3ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| ZNF280D | insertion | Frame_Shift_Ins | novel | c.1718_1719insAATTTTGAAAAAAGCACATA | p.Ser573ArgfsTer49 | p.S573Rfs*49 | Q6N043 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| ZNF280D | SNV | Missense_Mutation | novel | c.158N>T | p.Ser53Leu | p.S53L | Q6N043 | protein_coding | deleterious(0.02) | benign(0.244) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF280D | SNV | Missense_Mutation | novel | c.2726N>G | p.Asp909Gly | p.D909G | Q6N043 | protein_coding | deleterious(0.05) | probably_damaging(0.946) | TCGA-ZJ-AAX4-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF280D | insertion | Frame_Shift_Ins | rs747375742 | c.2376_2377insCTTT | p.Gly793LeufsTer9 | p.G793Lfs*9 | Q6N043 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | ||
| ZNF280D | SNV | Missense_Mutation | novel | c.2680G>T | p.Asp894Tyr | p.D894Y | Q6N043 | protein_coding | deleterious(0) | possibly_damaging(0.459) | TCGA-5M-AAT5-01 | Colorectum | colon adenocarcinoma | Unknown | Unknown | I/II | Unknown | Unknown | Unknown |
| ZNF280D | SNV | Missense_Mutation | c.1924A>G | p.Thr642Ala | p.T642A | Q6N043 | protein_coding | tolerated(0.52) | benign(0.009) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |